Nutraceutical composition and methods for preventing or treating multiple sclerosis

• US 20100311686A1
• Filed: 11/03/2009
• Published: 12/09/2010
• Est. Priority Date: 06/03/2009
• Status: Abandoned Application

• Current Assignee: The Trustees of Dartmounth College (Dartmouth College)
• Original Assignee: The Trustees of Dartmounth College (Dartmouth College)
• Inventors: Ochoa-Reparaz, Javier, Kasper, Lloyd H.
• Application Number:
  US12/611,627
• Publication Number:
  US 20100311686A1
• Time in Patent Office: Days
• US Class Current: 514/54
• CPC Class Codes: A23L 2/52 Adding ingredients adding preservatives A23L2/44
• CPC Class Codes: A23L 29/269 of microbial origin, e.g. xanthan or dextran
• CPC Class Codes: A23L 33/10 using additives addition of substantially indigestible substances A23L33/21
• CPC Class Codes: A23L 33/135 Bacteria or derivatives thereof, e.g. probiotics
• CPC Class Codes: A23L 33/40 Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/324 having an effect on the immune system
• CPC Class Codes: A23V 2250/206 Bacterial extracts
• CPC Class Codes: A23V 2250/51 Polysaccharide
• CPC Class Codes: A61K 2039/58 raising an immune response against a target which is not the antigen used for immunisation
• CPC Class Codes: A61K 2239/31 characterized by the route of administration
• CPC Class Codes: A61K 2239/38 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 31/203 Retinoic acids ; Salts thereof
• CPC Class Codes: A61K 31/4164 1,3-Diazoles
• CPC Class Codes: A61K 31/43 Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• CPC Class Codes: A61K 31/715 Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• CPC Class Codes: A61K 31/737 Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate A61K31/727 takes precedence
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61K 38/14 Peptides containing saccharide radicals; Derivatives thereof , e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
• CPC Class Codes: A61K 39/0216 Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
• CPC Class Codes: A61K 39/4611 : T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
• CPC Class Codes: A61K 39/4621 : immunosuppressive or immunotolerising
• CPC Class Codes: A61K 39/46433 : Antigens related to auto-immune diseases; Preparations to induce self-tolerance
• CPC Class Codes: A61K 45/06 : Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0053 : Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/0056 : Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• CPC Class Codes: A61K 9/0095 : Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006
• CPC Class Codes: A61P 25/00 : Drugs for disorders of the nervous system
• CPC Class Codes: A61P 37/00 : Drugs for immunological or allergic disorders
• CPC Class Codes: C12N 5/0636 : T lymphocytes

Abstract

The present invention embraces nutraceutical compositions containing isolated Bacteroides fragilis capsular polysaccharide A for use in methods of preventing or treating multiple sclerosis.

Claims

1. A nutraceutical comprising isolated Bacteroides fragilis capsular polysaccharide A and a nutritional source.

2. The nutraceutical of claim 1, wherein the Bacteroides fragilis capsular polysaccharide A is purified.

3. The nutraceutical of claim 1, wherein said nutraceutical is a food product, foodstuff, functional food, or a supplement composition for a food product or a foodstuff.

4. The nutraceutical composition of claim 1, wherein the amount of Bacteroides fragilis capsular polysaccharide A is 10 mg to 1000 mg per serving.

5. The nutraceutical composition of claim 1, wherein the amount of Bacteroides fragilis capsular polysaccharide A is 50 mg to 500 mg per serving.

6. The nutraceutical composition of claim 1, wherein the amount of Bacteroides fragilis capsular polysaccharide A is at least 150 mg per serving.

7. The nutraceutical composition of claim 1, wherein the amount of Bacteroides fragilis capsular polysaccharide A is at least 200 mg per serving.

8. The nutraceutical composition of claim 1, wherein said nutraceutical composition is prepared for oral consumption by a human subject.

9. The nutraceutical composition of claim 1, wherein said nutraceutical composition is configured to prevent or treat multiple sclerosis.

10. The nutraceutical composition of claim 1, wherein said nutritional source modulates endogenous commensal bacterial populations.

11. A commercial package containing as an active ingredient the nutraceutical composition of claim 1, together with instructions for its use in the prevention or treatment of multiple sclerosis.

12. The commercial package of claim 11, further comprising a natural product that modulates endogenous commensal bacterial populations.

13. A method for preventing or treating multiple sclerosis comprising administering to a subject in need of treatment an effective amount of isolated Bacteroides fragilis capsular polysaccharide A thereby preventing or treating multiple sclerosis.

14. The method of claim 13, wherein the Bacteroides fragilis capsular polysaccharide A is purified.

15. The method of claim 13, further comprising the prestep of administering an antibiotic.